29.07.2008 14:32:00
|
Millipore Names First Seed Grant Fellow
Millipore Corporation, a Life Science leader providing technologies,
tools and services for bioscience research and biopharmaceutical
manufacturing, today named acclaimed stem cell researcher Dr. Sangeeta
Bhatia as the first recipient of the Millipore Seed Grant Fellowship,
recently established in partnership with the Harvard Stem Cell Institute
(HSCI).
In 2008, Dr. Bhatia will receive $100,000 of the $500,000 Millipore
grant to HSCI announced last September and is eligible for continued
funding in 2009. The funds will be used to support her innovative
research in the area of embryonic stem cell differentiation.
"We are impressed with Dr. Bhatia’s
groundbreaking research, which combines cell biology and
micro-engineering,” said Geoffrey Crouse, Vice
President, Life Science Business Unit, Millipore Corporation. "Her
work will help advance the promising field of stem cell research by
increasing our understanding of the mechanisms of stem cell
differentiation. This type of research could lead to break-through
therapies for a whole host of medical conditions. Millipore is committed
to advancing life science research. We believe stem cells are critical
to improving drug safety and ultimately addressing major human health
issues.” "I’m honored to
receive this prestigious award,” said Dr.
Bhatia. "Having support and recognition from
the corporate community is imperative, and brings us closer to our goal
of curing life-threatening diseases such as cancer. I applaud Millipore
for its commitment to stem cell research.”
Dr. Bhatia currently serves as a biomedical engineer in the department
of Medicine at Brigham and Women’s Hospital
in Boston, Mass. and as professor of health sciences and technology, and
electrical engineering and computer science, at the Massachusetts
Institute of Technology (MIT) in Cambridge, Mass. She is the recipient
of many accolades and awards, including the American Institute for
Medical and Biological Engineering Fellowship, the American Society of
Mechanical Engineers Y. C. Fung Young Investigator Award and the
International Society of BioMEMS & Biomedical; Nanotechnology Scientific
Leadership Award. Dr. Bhatia earned her M.D. at Harvard Medical School
and doctorate in biomedical engineering and a master’s
degree in mechanical engineering from MIT, and a bachelor’s
degree in biomedical engineering from Brown University.
The Millipore Seed Grant Fellowship was established in September, 2007,
to direct the funding of Millipore’s
five-year, $500,000 grant to HSCI. Each year, beginning in 2008,
$100,000 will be earmarked for a Harvard-affiliated seed grant
recipient, selected from a list of candidates provided by HSCI.
The HSCI gift is Millipore’s first major
grant aimed at promoting stem cell research. A second grant, for
$150,000, was recently awarded to a scientist at the Scripps Research
Institute of California
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge
technologies, tools and services for bioscience research and
biopharmaceutical manufacturing. As a strategic partner, we collaborate
with customers to confront the world’s
challenging human health issues. From research to development to
production, our scientific expertise and innovative solutions help
customers tackle their most complex problems and achieve their goals.
Millipore Corporation is an S&P 500 company with 6,000 employees in 47
countries worldwide. For more information, please visit www.millipore.com.
The Millipore Corporate Giving Program, (formerly the Millipore
Foundation) seeks to contribute to the public good in ways that reflect
our values as a company at the frontier of scientific innovation. One of
our aims is to help Millipore employees make a positive difference in
the world around them. We pursue our goals by offering grants in the
areas of K–12 science education, bioscience
research, and local community support and by funding a series of
programs that encourage employee giving and volunteerism. For more
information, please visit www.millipore.com/foundation/mf3/millipore_foundation.
ADVANCING LIFE SCIENCE TOGETHERTM
Research. Development. Production.
About Harvard Stem Cell Institute
The Harvard Stem Cell Institute is a scientific collaborative within
Harvard University and its affiliated hospitals, established to fulfill
the promise of stem cell biology as a basis for cures and treatments for
a wide range of chronic and medical conditions. HSCI takes a broad
approach, focusing not only on stem cell science, but also on teacher
education and programs in bioethics and the public policy issues
generated by stem cell research. For more information, visit www.hsci.harvard.edu.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Merck KGaAmehr Nachrichten
Analysen zu Merck KGaAmehr Analysen
09.01.25 | Merck Buy | Goldman Sachs Group Inc. | |
07.01.25 | Merck Market-Perform | Bernstein Research | |
11.12.24 | Merck Overweight | JP Morgan Chase & Co. | |
03.12.24 | Merck Overweight | JP Morgan Chase & Co. | |
02.12.24 | Merck Kaufen | DZ BANK |
Aktien in diesem Artikel
Merck KGaA | 142,20 | 0,35% |
Indizes in diesem Artikel
S&P 500 | 5 819,30 | -1,67% |